OBJECTIVE: Most collaborative studies for the treatment of primary and recurrent ovarian cancer have grouped all epithelial ovarian cancers together, leading to a common therapeutic approach to all the different subtypes. Emerging data, however, support the hypothesis that primary mucinous ovarian cancers are unique histologically, molecularly, and clinically from other epithelial subtypes. The objective of our review was to identify and synthesize the most current information on mucinous ovarian carcinoma with regard to pathologic, molecular, and clinical distinctions. METHODS: We searched PubMed for English-language articles with the MeSH term "mucinous ovarian carcinoma" published between 1990 and 2009. RESULTS: On pathologic examination, primary invasive mucinous ovarian cancer often can be seen next to areas of benign and borderline mucinous histology, suggesting a continuum to malignant progression not observed in the other epithelial ovarian lesions. When compared to serous ovarian tumors, primary mucinous ovarian tumors have a significantly higher prevalence of KRAS mutations and a lower frequency of BRCA and p53 abnormalities. In addition, metastatic primary disease and recurrent mucinous cancers have a substantially worse prognosis than other epithelial ovarian cancers and are largely platinum and taxane resistant. CONCLUSIONS: Primary mucinous ovarian cancer should be considered separate from the other epithelial ovarian cancers. Ongoing clinical trials in this disease will likely offer improvements in chemotherapeutic agents used to treat women with primary and recurrent mucinous ovarian cancer. Copyright 2010 Elsevier Inc. All rights reserved.
OBJECTIVE: Most collaborative studies for the treatment of primary and recurrent ovarian cancer have grouped all epithelial ovarian cancers together, leading to a common therapeutic approach to all the different subtypes. Emerging data, however, support the hypothesis that primary mucinous ovarian cancers are unique histologically, molecularly, and clinically from other epithelial subtypes. The objective of our review was to identify and synthesize the most current information on mucinous ovarian carcinoma with regard to pathologic, molecular, and clinical distinctions. METHODS: We searched PubMed for English-language articles with the MeSH term "mucinous ovarian carcinoma" published between 1990 and 2009. RESULTS: On pathologic examination, primary invasive mucinous ovarian cancer often can be seen next to areas of benign and borderline mucinous histology, suggesting a continuum to malignant progression not observed in the other epithelial ovarian lesions. When compared to serous ovarian tumors, primary mucinous ovarian tumors have a significantly higher prevalence of KRAS mutations and a lower frequency of BRCA and p53 abnormalities. In addition, metastatic primary disease and recurrent mucinous cancers have a substantially worse prognosis than other epithelial ovarian cancers and are largely platinum and taxane resistant. CONCLUSIONS:Primary mucinous ovarian cancer should be considered separate from the other epithelial ovarian cancers. Ongoing clinical trials in this disease will likely offer improvements in chemotherapeutic agents used to treat women with primary and recurrent mucinous ovarian cancer. Copyright 2010 Elsevier Inc. All rights reserved.
Authors: F M Muggia; P S Braly; M F Brady; G Sutton; T H Niemann; S L Lentz; R D Alvarez; P R Kucera; J M Small Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: Colin J R Stewart; Barbara A Brennan; Ian G Hammond; Yee C Leung; Anthony J McCartney Journal: Int J Gynecol Pathol Date: 2005-10 Impact factor: 2.762
Authors: M J Piccart; K Bertelsen; K James; J Cassidy; C Mangioni; E Simonsen; G Stuart; S Kaye; I Vergote; R Blom; R Grimshaw; R J Atkinson; K D Swenerton; C Trope; M Nardi; J Kaern; S Tumolo; P Timmers; J A Roy; F Lhoas; B Lindvall; M Bacon; A Birt; J E Andersen; B Zee; J Paul; B Baron; S Pecorelli Journal: J Natl Cancer Inst Date: 2000-05-03 Impact factor: 13.506
Authors: Anna V Yemelyanova; Russell Vang; Kara Judson; Lee-Shu-Fune Wu; Brigitte M Ronnett Journal: Am J Surg Pathol Date: 2008-01 Impact factor: 6.394
Authors: S C Mok; D A Bell; R C Knapp; P M Fishbaugh; W R Welch; M G Muto; R S Berkowitz; S W Tsao Journal: Cancer Res Date: 1993-04-01 Impact factor: 12.701
Authors: Katherine C Kurnit; Abdulrahman K Sinno; Bryan M Fellman; Aaron Varghese; Rebecca Stone; Anil K Sood; David M Gershenson; Kathleen M Schmeler; Anais Malpica; Amanda N Fader; Michael Frumovitz Journal: Obstet Gynecol Date: 2019-12 Impact factor: 7.661
Authors: Cristóbal Aguilar-Gallardo; Emily Cecilia Rutledge; Ana M Martínez-Arroyo; Juan José Hidalgo; Santiago Domingo; Carlos Simón Journal: Stem Cell Rev Rep Date: 2012-09 Impact factor: 5.739
Authors: Koji Matsuo; Masato Nishimura; Justin N Bottsford-Miller; Jie Huang; Kakajan Komurov; Guillermo N Armaiz-Pena; Mian M K Shahzad; Rebecca L Stone; Ju Won Roh; Angela M Sanguino; Chunhua Lu; Dwight D Im; Neil B Rosenshien; Atsuko Sakakibara; Tadayoshi Nagano; Masato Yamasaki; Takayuki Enomoto; Tadashi Kimura; Prahlad T Ram; Kathleen M Schmeler; Gary E Gallick; Kwong K Wong; Michael Frumovitz; Anil K Sood Journal: Clin Cancer Res Date: 2011-07-07 Impact factor: 12.531
Authors: Koji Matsuo; Yongmei Huang; Oliver Zivanovic; Muneaki Shimada; Hiroko Machida; Brendan H Grubbs; Lynda D Roman; Jason D Wright Journal: Gynecol Oncol Date: 2019-07-04 Impact factor: 5.482
Authors: Tao Liu; Wei Hu; Heather J Dalton; Hyun Jin Choi; Jie Huang; Yu Kang; Sunila Pradeep; Takahito Miyake; Jian H Song; Yunfei Wen; Chunhua Lu; Chad V Pecot; Justin Bottsford-Miller; Behrouz Zand; Nicholas B Jennings; Cristina Ivan; Gary E Gallick; Keith A Baggerly; David G Hangauer; Robert L Coleman; Michael Frumovitz; Anil K Sood Journal: Clin Cancer Res Date: 2013-10-07 Impact factor: 12.531
Authors: Koji Matsuo; Hiroko Machida; Shinya Matsuzaki; Brendan H Grubbs; Maximilian Klar; Lynda D Roman; Anil K Sood; David M Gershenson; Jason D Wright Journal: Gynecol Oncol Date: 2020-01-15 Impact factor: 5.482
Authors: Takeshi Hisamatsu; Michael McGuire; Sherry Y Wu; Rajesha Rupaimoole; Sunila Pradeep; Emine Bayraktar; Kyunghee Noh; Wei Hu; Jean M Hansen; Yasmin Lyons; Kshipra M Gharpure; Archana S Nagaraja; Lingegowda S Mangala; Takashi Mitamura; Cristian Rodriguez-Aguayo; Young Gyu Eun; Johnathon Rose; Geoffrey Bartholomeusz; Cristina Ivan; Ju-Seog Lee; Koji Matsuo; Michael Frumovitz; Kwong K Wong; Gabriel Lopez-Berestein; Anil K Sood Journal: Mol Cancer Ther Date: 2018-10-10 Impact factor: 6.261